IRCT201302261030N12已完成2 期
Efficacy of Imatinib Mesylate in the treatment of refractory cutaneous chronic Graft Versus-Host Disease
Hematology-Oncology and SCT Research Center0 个研究点目标入组 28 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16 years 至 60 years（—）
- 性别
- All
入选标准
- •Inclusion Criteria
- •1- The patient shall undergo allogen bone marrow transplantation and have clinical and pathological cutaneous CGVHD criteria.
- •2- Patient’s cutaneous signs are not improved by taking corticosteroids with doses of 0.5 mg/kg at least for 3 months and cyclosporine.
- •3- The cutaneous signs shall be active.
- •4- The patient shall be aged between 16 to 60 years old.
- •Exclusion Criteria
- •1- Pregnancy
- •2- Having a history of taking Rituximab.
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Phase II study of imatinib mesylate for treatment of Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in children: A Japanese Cooperative TrialPhiladelphia Chromosome-positive acute lymphoblastic leukemiaJPRN-C000000290Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)56
进行中（未招募）
不适用
THERAPEUTIC AND BIOLOGICAL EFFECTS OF IMATINIB MESYLATE (STI571) IN PRIMARY HYPERESINOPHILIC SYNDROME (HES), CHRONIC EOSINOPHILIC LEUKEMIA (CEL) AND CHRONIC IDIOPHATIC HYPEREOSINOPHILIA (CIH): A STUDY FROM THE NORTHEN ITALY LEUKEMIA GROUP (NILG)EUCTR2004-002280-24-ITAZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO (A.O. DI RILIEVO NAZIONALE)
招募中
1 期
Safety and efficacy of imatinib therapy administered in patients with Pulmonary Tumor Thrombotic Microangiopathy (PTTM) : A prospective studyPatients with malignancy, suspected of Pulmonary Tumor Thrombotic Microangiopathy (PTTM)JPRN-jRCTs031210263Hatano Masaru20
已完成
3 期
se of memantin in treatment of adult with attention deficit hyperactivity disorderAdult ADHD (Attention-deficit hyperactivity disorder ).Disturbance of activity and attentionIRCT2016053028182N1Kurdistan University of Medical science40
进行中（未招募）
1 期
Efficacy of adjuvant Imatinib in patients with intermediate-risk gastrointestinal stromal tumor with a high-risk Genomic Grade Index. Multicenter, prospective, randomized study.Patients with intermediate-risk gastrointestinal stromal tumor presenting a high Genomic Grade IndexEUCTR2014-005255-87-FRAssistance Publique Hôpitaux de MARSEILLE80